Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIORESAL vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
FDA-approved: Intrathecal: severe spasticity of cerebral or spinal origin; Oral: spasticity in multiple sclerosis, spinal cord injury. Off-label: Trigeminal neuralgia, essential tremor, chronic hiccups, alcohol withdrawal, stiff-person syndrome, dystonia, gastroesophageal reflux disease, epilepsy, autism, cluster headaches, intractable hiccups, cocaine dependence, Huntington disease, Tourette syndrome, tardive dyskinesia, periodic limb movement disorder, myoclonus, apraxia of eyelid opening, hemifacial spasm, nystagmus, tic disorders, generalized anxiety disorder, insomnia, and chronic hiccup.
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic metabolism via deamination (minor pathway); primarily excreted unchanged in urine (70-80% as parent drug, 15% as metabolites).
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
~30%; primarily bound to albumin.
Approximately 90–95% bound, primarily to albumin.
0.5-1.0 L/kg; indicates moderate tissue distribution, with higher CNS penetration when administered intrathecally.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 70-80% (first-pass effect minimal); intrathecal: nearly 100% due to direct CSF administration.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
GFR >60 m L/min: no adjustment; GFR 30-60: reduce dose by 25-50%; GFR <30: avoid or reduce by 75%; hemodialysis: supplement dose after dialysis.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Oral: 2.5 mg 4 times daily initially, increase by 2.5-5 mg every 3 days to max 40 mg/day (2-7 years) or 60 mg/day (8-15 years). Intrathecal: test dose 25-50 mcg; maintenance 100-1000 mcg/day.
Not established; safety and efficacy not studied in pediatric patients.
Start at 5 mg twice daily; increase slowly due to increased CNS sensitivity; monitor for sedation and confusion.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Abrupt discontinuation of intrathecal baclofen may result in life-threatening withdrawal reactions (high fever, altered mental status, severe spasticity, rhabdomyolysis, autonomic dysfunction).
None
Abrupt discontinuation: may cause withdrawal symptoms (hallucinations, seizures, hyperthermia, rebound spasticity). Sedation: may impair ability to drive or operate machinery. Renal impairment: dose adjustment required. Avoid concomitant use with CNS depressants (alcohol, benzodiazepines). Caution in stroke patients, respiratory depression, psychiatric disorders, epilepsy, and pregnancy.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Absolute: Hypersensitivity to baclofen or any component; concomitant use of oral baclofen and intrathecal baclofen; intrathecal use contraindicated in patients with IV access device infection, spinal canal obstruction, or bleeding diathesis. Relative: Renal impairment, hepatic impairment, respiratory insufficiency, seizure disorder, history of autonomic dysreflexia, pregnancy, and lactation.
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
No specific food interactions, but take with or without food consistently to avoid variable absorption.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia, and withdrawal symptoms (irritability, tremors) in neonates. Use only if benefit outweighs risk.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Lioresal (baclofen) is excreted into human breast milk in low concentrations; M/P ratio is approximately 0.4-0.7. No adverse effects reported in nursing infants. Caution advised, especially in preterm infants or those with renal impairment.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Dose should be titrated to lowest effective dose, with close monitoring for efficacy and toxicity. No specific dose adjustment guidelines; individualize based on clinical response.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Titrate slowly to avoid sedation and muscle weakness; monitor for withdrawal signs after abrupt discontinuation (e.g., spasticity rebound, hyperpyrexia, seizures). Intrathecal pump requires specialist management.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take exactly as prescribed; do not suddenly stop taking this medication.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Report any unusual muscle weakness, confusion, or difficulty breathing.,Keep medication in original container away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIORESAL vs CHLORZOXAZONE, answered by our medical review team.
LIORESAL is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIORESAL and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIORESAL is: Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIORESAL and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIORESAL is classified as Category C. First trimester: Increased risk of orofacial clefts (cleft palate) based on animal studies and limited human data. Second and third trimesters: Risk of fetal bradycardia, hypotonia. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.